Logo image of PULM

PULMATRIX INC (PULM) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PULM - US74584P3010 - Common Stock

2.36 USD
+0.01 (+0.43%)
Last: 1/9/2026, 8:19:06 PM
Fundamental Rating

3

Taking everything into account, PULM scores 3 out of 10 in our fundamental rating. PULM was compared to 191 industry peers in the Pharmaceuticals industry. While PULM has a great health rating, there are worries on its profitability. PULM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

PULM had negative earnings in the past year.
PULM had a negative operating cash flow in the past year.
In the past 5 years PULM always reported negative net income.
In the past 5 years PULM always reported negative operating cash flow.
PULM Yearly Net Income VS EBIT VS OCF VS FCFPULM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

With a Return On Assets value of -124.85%, PULM is not doing good in the industry: 81.68% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -131.42%, PULM is doing worse than 67.54% of the companies in the same industry.
Industry RankSector Rank
ROA -124.85%
ROE -131.42%
ROIC N/A
ROA(3y)-61.24%
ROA(5y)-54.83%
ROE(3y)-81.96%
ROE(5y)-75.71%
ROIC(3y)N/A
ROIC(5y)N/A
PULM Yearly ROA, ROE, ROICPULM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

PULM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PULM Yearly Profit, Operating, Gross MarginsPULM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

7

2. Health

2.1 Basic Checks

PULM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PULM has about the same amount of shares outstanding.
The number of shares outstanding for PULM has been increased compared to 5 years ago.
PULM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PULM Yearly Shares OutstandingPULM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
PULM Yearly Total Debt VS Total AssetsPULM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -67.00, we must say that PULM is in the distress zone and has some risk of bankruptcy.
PULM's Altman-Z score of -67.00 is on the low side compared to the rest of the industry. PULM is outperformed by 93.72% of its industry peers.
PULM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -67
ROIC/WACCN/A
WACC9.46%
PULM Yearly LT Debt VS Equity VS FCFPULM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 19.97 indicates that PULM has no problem at all paying its short term obligations.
PULM's Current ratio of 19.97 is amongst the best of the industry. PULM outperforms 89.53% of its industry peers.
A Quick Ratio of 19.97 indicates that PULM has no problem at all paying its short term obligations.
The Quick ratio of PULM (19.97) is better than 89.53% of its industry peers.
Industry RankSector Rank
Current Ratio 19.97
Quick Ratio 19.97
PULM Yearly Current Assets VS Current LiabilitesPULM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

4

3. Growth

3.1 Past

PULM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.59%, which is quite impressive.
The Revenue for PULM has decreased by -99.97% in the past year. This is quite bad
Measured over the past years, PULM shows a decrease in Revenue. The Revenue has been decreasing by -0.26% on average per year.
EPS 1Y (TTM)35.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.1%
Revenue 1Y (TTM)-99.97%
Revenue growth 3Y14.72%
Revenue growth 5Y-0.26%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 23.43% on average over the next years. This is a very strong growth
PULM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 43.66% yearly.
EPS Next Y-10%
EPS Next 2Y22.57%
EPS Next 3Y28.64%
EPS Next 5Y23.43%
Revenue Next Year1%
Revenue Next 2Y54.02%
Revenue Next 3Y58.32%
Revenue Next 5Y43.66%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PULM Yearly Revenue VS EstimatesPULM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
PULM Yearly EPS VS EstimatesPULM Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PULM. In the last year negative earnings were reported.
Also next year PULM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PULM Price Earnings VS Forward Price EarningsPULM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PULM Per share dataPULM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PULM's earnings are expected to grow with 28.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.57%
EPS Next 3Y28.64%

0

5. Dividend

5.1 Amount

No dividends for PULM!.
Industry RankSector Rank
Dividend Yield 0%

PULMATRIX INC

NASDAQ:PULM (1/9/2026, 8:19:06 PM)

2.36

+0.01 (+0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-16 2025-10-16
Earnings (Next)03-19 2026-03-19/bmo
Inst Owners9.47%
Inst Owner Change0%
Ins Owners0.66%
Ins Owner Change0%
Market Cap8.61M
Revenue(TTM)3.00K
Net Income(TTM)-6.22M
Analysts82.86
Price TargetN/A
Short Float %0.12%
Short Ratio0.26
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2871.33
P/FCF N/A
P/OCF N/A
P/B 1.82
P/tB 1.82
EV/EBITDA N/A
EPS(TTM)-1.7
EYN/A
EPS(NY)-2.28
Fwd EYN/A
FCF(TTM)-1.64
FCFYN/A
OCF(TTM)-1.64
OCFYN/A
SpS0
BVpS1.3
TBVpS1.3
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -124.85%
ROE -131.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.24%
ROA(5y)-54.83%
ROE(3y)-81.96%
ROE(5y)-75.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.97
Quick Ratio 19.97
Altman-Z -67
F-Score3
WACC9.46%
ROIC/WACCN/A
Cap/Depr(3y)312.07%
Cap/Depr(5y)229.17%
Cap/Sales(3y)5.28%
Cap/Sales(5y)4.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.1%
EPS Next Y-10%
EPS Next 2Y22.57%
EPS Next 3Y28.64%
EPS Next 5Y23.43%
Revenue 1Y (TTM)-99.97%
Revenue growth 3Y14.72%
Revenue growth 5Y-0.26%
Sales Q2Q%-100%
Revenue Next Year1%
Revenue Next 2Y54.02%
Revenue Next 3Y58.32%
Revenue Next 5Y43.66%
EBIT growth 1Y16.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y69.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y68.52%
OCF growth 3YN/A
OCF growth 5YN/A

PULMATRIX INC / PULM FAQ

Can you provide the ChartMill fundamental rating for PULMATRIX INC?

ChartMill assigns a fundamental rating of 3 / 10 to PULM.


Can you provide the valuation status for PULMATRIX INC?

ChartMill assigns a valuation rating of 1 / 10 to PULMATRIX INC (PULM). This can be considered as Overvalued.


How profitable is PULMATRIX INC (PULM) stock?

PULMATRIX INC (PULM) has a profitability rating of 0 / 10.


What is the financial health of PULMATRIX INC (PULM) stock?

The financial health rating of PULMATRIX INC (PULM) is 7 / 10.


Can you provide the expected EPS growth for PULM stock?

The Earnings per Share (EPS) of PULMATRIX INC (PULM) is expected to decline by -10% in the next year.